These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 9839277)
1. Angiotensin II, nitric oxide, and end-organ damage in hypertension. Bataineh A; Raij L Kidney Int Suppl; 1998 Dec; 68():S14-9. PubMed ID: 9839277 [TBL] [Abstract][Full Text] [Related]
2. Nitric oxide, angiotensin II, and hypertension. Zhou MS; Schulman IH; Raij L Semin Nephrol; 2004 Jul; 24(4):366-78. PubMed ID: 15252776 [TBL] [Abstract][Full Text] [Related]
3. Nitric oxide in hypertension: relationship with renal injury and left ventricular hypertrophy. Raij L Hypertension; 1998 Jan; 31(1 Pt 2):189-93. PubMed ID: 9453301 [TBL] [Abstract][Full Text] [Related]
4. The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hayakawa H; Raij L Hypertension; 1997 Jan; 29(1 Pt 2):235-41. PubMed ID: 9039108 [TBL] [Abstract][Full Text] [Related]
5. Workshop: hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Raij L Hypertension; 2001 Feb; 37(2 Pt 2):767-73. PubMed ID: 11230371 [TBL] [Abstract][Full Text] [Related]
6. Nitric oxide, angiotensin II, and reactive oxygen species in hypertension and atherogenesis. Schulman IH; Zhou MS; Raij L Curr Hypertens Rep; 2005 Feb; 7(1):61-7. PubMed ID: 15683588 [TBL] [Abstract][Full Text] [Related]
7. Interaction between nitric oxide and angiotensin II in the endothelium: role in atherosclerosis and hypertension. Schulman IH; Zhou MS; Raij L J Hypertens Suppl; 2006 Mar; 24(1):S45-50. PubMed ID: 16601573 [TBL] [Abstract][Full Text] [Related]
8. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Hayakawa H; Coffee K; Raij L Circulation; 1997 Oct; 96(7):2407-13. PubMed ID: 9337217 [TBL] [Abstract][Full Text] [Related]
9. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Zhuo JL; Mendelsohn FA; Ohishi M Hypertension; 2002 Feb; 39(2 Pt 2):634-8. PubMed ID: 11882622 [TBL] [Abstract][Full Text] [Related]
10. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease? Ruschitzka FT; Lüscher TF Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622 [TBL] [Abstract][Full Text] [Related]
11. Nitric oxide synthase activity and renal injury in genetic hypertension. Hayakawa H; Raij L Hypertension; 1998 Jan; 31(1 Pt 2):266-70. PubMed ID: 9453314 [TBL] [Abstract][Full Text] [Related]
12. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. Enseleit F; Hürlimann D; Lüscher TF J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475 [TBL] [Abstract][Full Text] [Related]
13. Renin-angiotensin blockade improves renal cGMP production via non-AT(2)-receptor mediated mechanisms in hypertension-induced by chronic NOS inhibition in rat. Uhlenius N; Vuolteenaho O; Tikkanen I J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):233-9. PubMed ID: 11881129 [TBL] [Abstract][Full Text] [Related]
14. Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia. Long CL; Qin XC; Pan ZY; Chen K; Zhang YF; Cui WY; Liu GS; Wang H J Hypertens; 2008 Dec; 26(12):2326-38. PubMed ID: 19008712 [TBL] [Abstract][Full Text] [Related]
15. Vasculoprotective and cardioprotective mechanisms of angiotensin-converting enzyme inhibition: the homeostatic balance between angiotensin II and nitric oxide. Gibbons GH Clin Cardiol; 1997 Nov; 20(11 Suppl 2):II-18-25. PubMed ID: 9422848 [TBL] [Abstract][Full Text] [Related]
16. The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats. Paulo LL; Cruz JC; Zhuge Z; Carvalho-Galvão A; Brandão MCR; Diniz TF; Haworth SM; Athayde-Filho PF; Lemos VS; Lundberg JO; Montenegro MF; Braga VA; Carlström M Redox Biol; 2018 May; 15():182-191. PubMed ID: 29268201 [TBL] [Abstract][Full Text] [Related]
17. In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II. Zhou MS; Adam AG; Jaimes EA; Raij L Hypertension; 2003 Nov; 42(5):945-51. PubMed ID: 12975388 [TBL] [Abstract][Full Text] [Related]
18. Angiotensin II type 1 receptor blockade restores nitric oxide-dependent renal vascular responses in renovascular hypertension. Martinez Y; Martinez S; Meaney A; Meaney E; Escalante B J Cardiovasc Pharmacol; 2002 Sep; 40(3):381-7. PubMed ID: 12198324 [TBL] [Abstract][Full Text] [Related]
19. Calcium channel blockers, endothelial dysfunction, and combination therapy. Schulman IH; Zachariah M; Raij L Aging Clin Exp Res; 2005 Aug; 17(4 Suppl):40-5. PubMed ID: 16640172 [TBL] [Abstract][Full Text] [Related]
20. Nitric oxide--angiotensin II axis in renal and cardiovascular injury. Adam A; Raij L J Nephrol; 2000; 13(3):211-20. PubMed ID: 10928298 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]